Guillain-Barre Syndrome: A Review

GBS is a rare but serious neurological disorder in which the immune system mistakenly targets the nerves, causing muscle weakness, tingling, and, in severe cases, paralysis. First identified in 1916, GBS has several variations, including acute inflammatory demyelinating polyneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and Miller Fisher Syndrome (MFS). Although its exact cause remains unclear, it is often triggered by infections, vaccinations, surgery, or autoimmune conditions. The disorder disrupts nerve communication by damaging either the protective myelin sheath or the nerve fibres themselves, leading to motor and autonomic dysfunction. Diagnosis is based on symptoms, cerebrospinal fluid analysis, and nerve studies. Treatment primarily involves modulating the immune response through intravenous immunoglobulin (IVIG) or plasma exchange, along with supportive care and rehabilitation. While most individuals recover within a year, some may experience persistent weakness or complications. Advances in medical research have significantly improved recovery rates, but further studies are needed to enhance understanding and prevention of the condition.